Heart Disease Type 1 Diabetes Metformin Research Reveals Alarming New Findings
Scientists at Newcastle University have identified the mechanism by which metformin, a commonly prescribed Type 2 diabetes drug, prevents heart disease in patients with Type 1 diabetes. Published in the International Journal of Molecular Sciences, the findings from the MERIT clinical trial open the door to new treatment strategies that go well beyond blood sugar management. According to the Mayo Clinic, cardiovascular disease is one of the leading complications of Type 1 diabetes and outcomes are significantly worse in diabetic patients than in the general population.
Why Heart Disease Risk Is Elevated in Type 1 Diabetes
Outcomes of heart disease are measurably worse in patients with diabetes compared to those without the condition. Despite this well established risk, there have historically been very few treatment options specifically targeting heart disease Type 1 diabetes prevention. Metformin is widely used in Type 2 diabetes to lower blood sugar by reducing glucose production in the liver, but it is not routinely prescribed for Type 1 diabetes patients.
The MERIT trial was the first to test whether metformin could also provide heart disease prevention benefits specifically for Type 1 diabetes patients, building on earlier work that had suggested vascular improvements in this population.
How Metformin Protects the Heart in Type 1 Diabetes
The key finding in this heart disease Type 1 diabetes metformin research is the role of microRNAs, or miRs, in the vascular damage process. MicroRNAs are messenger molecules that regulate gene expression across different cell types. In Type 1 diabetic patients, three specific anti-angiogenic microRNAs, miR-222, miR-195, and miR-21a, were found at elevated levels compared to healthy controls. Elevated levels of these molecules suppress the growth of new blood vessels and impair the body’s ability to repair damaged vascular tissue.
Metformin treatment successfully reduced the levels of all three of these microRNAs, restoring the conditions needed for improved vascular repair. As lead author Dr. Jolanta Weaver, Senior Lecturer in Diabetes Medicine at Newcastle University, explained, the drug is working both to improve blood sugar control and to protect the heart through a distinct and previously unidentified pathway.
3 Alarming Findings From the Heart Disease Type 1 Diabetes Metformin Trial
1. Metformin Reduced Harmful MicroRNA Levels in Type 1 Diabetic Patients
At the start of the MERIT study, miR-222, miR-195, and miR-21a were all significantly elevated in Type 1 diabetic patients compared to the healthy control group. After eight weeks of metformin treatment, all three microRNA levels were reduced, demonstrating a direct pharmacological effect on the molecular pathways driving vascular damage in heart disease Type 1 diabetes patients.
2. Lowering miR-222 Improved Vascular Repair Markers
As levels of miR-222 decreased following metformin treatment, there was a corresponding reduction in circulating endothelial cells. This reduction indicates an improvement in vascular repair activity, meaning the lining of blood vessels was showing signs of recovering its normal regenerative function. This is a significant finding for heart disease Type 1 diabetes management because vascular damage is a core driver of cardiovascular complications in this population.
3. The Study Opens a New Therapeutic Pathway Based on MicroRNA Regulation
The research team identified for the first time that metformin achieves its heart protective effects in Type 1 diabetes by lowering the presence of anti-angiogenic microRNAs. This mechanistic clarity creates a foundation for developing new therapies specifically designed to regulate microRNA levels in diabetic patients, potentially achieving cardiovascular protection even in patients who cannot take or do not respond to metformin directly.
What Comes Next
The Newcastle team will continue developing the heart disease Type 1 diabetes metformin findings with the goal of creating new treatments based on microRNA regulation. As Dr. Weaver noted, understanding the underlying mechanism opens up entirely new possibilities for reducing the risk of cardiovascular disease in Type 1 diabetic patients, a population that has long lacked targeted preventive options.
FOMAT conducts Phase I through Phase IV clinical research across a national network of investigator sites throughout the United States. To learn more about active cardiovascular and metabolic studies, visit our patient active studies page.